Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Boehringer Ingelheim
Biotech
Ose narrows focus to conserve cash at expense of wider pipeline
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
James Waldron
Dec 9, 2025 9:41am
Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist
Nov 13, 2025 9:52am
FDA reveals 2nd round of 'national priority' voucher winners
Nov 6, 2025 3:12pm
Boehringer's deal frenzy continues with $570M autoimmune pact
Nov 4, 2025 8:00am
Boehringer returns to Kyowa with €640M pact for autoimmune drug
Oct 30, 2025 6:03am
Boehringer digs in on ADCs with $991M AimedBio licensing accord
Oct 15, 2025 10:05am
